

Dr Matthew Streetly's publications:

Streetly M. Myeloma and MGUS. *Medicine*. 2013 May;41(5) 295-8 Moore S, Atwal S, Sachchithanantham S, Streetly M, Khan I, Percy L, Narat S, D'Sa S, Rabin N, Johnston R, Schey S, Yong K. Weekly intravenous bortezomib is ineffective and well tolerated in relapsed /refractory myeloma. *Eur J Haematol*. 2013 May;90(5):420-5

Yapa HM, McLornan DP, Raj K, Streetly M, Kazmi M, Cuthill K, Laurie J, Menon PA, Macmahon E. Pneumonitis post-haematopoietic stem cell transplant - cytopathology clinches diagnosis. *J Clin Virol*. 2012 Nov;55(3):278-81.

Morris C, Cook G, Streetly M, Kettle P, Drake M, Quinn M, Cavet J, Tighe J, Kazmi M, Ashcroft J, Cook M, Snowden J, Olujohungbe A, Marshall S, Conn J, Oakervee H, Popat R, Cavenagh J. Re transplantation after bortezomib-based therapy. *Br J Haematol*. 2011 Jun;153(5):666-8.

Hodson A, Kasliwal M, Streetly M, MacMahon E, Raj K. A parainfluenza-3 outbreak in a SCT unit: sepsis with multi-organ failure and multiple co-pathogens are associated with increased mortality. *Bone Marrow Transplant*. 2011 Dec;46(12):1545-50.

Streetly MJ, Maharaj L, Joel S, Schey SA, Gribben JG, Cotter FE. GCS-100, a novel galectin-3 antagonist, modulates MCL-1, NOXA, and cell cycle to induce myeloma cell death. *Blood*. 2010 May 13;115(19):3939-48.

Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. *Br J Haematol*. 2008 Apr;141(1):41-51.

McCarthy DA, Macey MG, Streetly M, Schey SA, Brown KA. The neutropenia induced by the thalidomide analogue CC-4047 in patients with multiple myeloma is associated with an increased percentage of neutrophils bearing CD64. *Int Immunopharmacol*. 2006 Jul;6(7):1194-203.

Streetly M, Hunt BJ, Parmar K, Jones R, Zeldis J, Schey S. Markers of endothelial and haemostatic function in the treatment of relapsed myeloma with the immunomodulatory agent Actimid (CC-4047) and their relationship with venous thrombosis. *Eur J Haematol*. 2005 Apr;74(4):293-6.

Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, Streetly M, Dalglish AG. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. *J Clin Oncol*. 2004 Aug 15;22(16):3269-76.

Streetly M, Kazmi M, Radia D, Hoyle C, Schey SA. Second autologous transplant with cyclosporin/interferon alpha-induced graft versus host disease

for patients who have failed first-line consolidation. Bone Marrow Transplant.
2004 Jun;33(11):1131-5.